Nuclear Medicine ( Y-90) Therapy Center is staffed with an experienced and highly professional medical team. It is equipped with precise NM/CT 860 SPECT/CT and IGS5 DSA made by GE, which can well demonstrate the in tegrated diagnosis and treatment. Moreover, 99mTc, MAA hepatic artery perfusion imaging, Yttrium-90 brems strahlung imaging, Iodine 131 whole body imaging, whold body bone imaging, renal dynamic imaging (RDI), thyroid imaging, salivary gland imaging and myocardial imaging are also conducted to assist nuclide treatment and clinical diagnosis. On the top of nuclide therapy, it works with minimally invasive surgery department to conduct leading-edge treatment like Yttrium-90 program, intracavitary injection of radioactive colloids for ma lignant hydrothorax, strontium 89/radium 223 tumor bone metastasis treatment and praseodymium 177-PSMA prostate cancer treatment based on utilization of Iodine 131 therapy for differentiated thyroid cancer ward.

Nuclide ward

Patients with liver cancer, including primary or metastatic liver malignant tumors, espe cially patients with advanced liver cancer and other unresectable liver tumors, receive selective internal radiotherapy with yttrium 90 microspheres, which brings hope and opportunity for more patients with advanced liver cancer to achieve clinical cure and return to normal life.

To this end, the Department of Nuclear Medicine, the Department of Minimally Inva sive Intervention and the Department of Hepatobiliary Surgery of Guangzhou Royal Li Hospital have set up a multidisciplinary expert team of yttrium 90 microspheres for the clinical treatment of liver malignant tumors. The hospital has obtained the relevant radiotherapy license, making Guangzhou Royal Li Hospital one of the few medical insti tutions in the country that can standardize the technology.

Advantages of yttrium 90 in the treatment of liver cancer

The effect of reducing tumor is remarkable.
Yttrium 90 microsphere therapy has the dual efficacy of strong tumor shrinkage and increasing the volume of residual liver, which makes it an ideal choice for pa tients with initial unresectable liver cancer to achieve down-stage and conversion therapy.

Precisely targeted to kill cancer tissue.
It can almost not damage the sur rounding normal liver tissue, max imize the retention of residual liver volume, and has higher success rate of treatment, longer survival time without progress, less side effects on human body and safer.

The complete elimination rate of lesions was high, and the micro vascular invasion was reduced.
Compared with TACE therapy, yt trium 90 can achieve a high CPN rate, effectively reduce microvas cular invasion, and reduce the re currence rate after transplantation.

The treatment cycle is short, the adverse reaction is few.
Yttrium 90 microspheres thera py has the advantages of precise treatment, small trauma and mild side effects.Therefore, it can also be used for the first-line treatment of elderly patients in clinic.